Clinical trial · Interventional
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT00294931CI-TRIAL-00003601completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Small Cell Lung | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Drug | Bevacizumab | ALIAS |
| carboplatin | Drug | Carboplatin | ALIAS |
| irinotecan | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- median time to progression
Secondary outcomes (4)
- measure
- overall toxicity
- measure
- overall response rate
- measure
- duration of response
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed small cell lung cancer,extensive stage disease. * Measurable or evaluable disease * No previous chemotherapy * Able to perform activities of daily living with minimal assistance * Adequate hematological, live and kidney function * Provide written informed consent Exclusion Criteria: * Limited stage disease * PEG or G tubes * Hemoptysis * Abdominal fistula, perforation, or abscess within the previous 6 months * Women who are pregnant or lactating * Proteinuria * Serious nonhealing wound, ulcer, or bone fracture * Evidence of bleeding diathesis or coagulopathy * Uncontrolled or serious cardiovascular disease * Uncontrolled brain metastasis * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days * Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment
References
Publications (1)
- RESULTSpigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, Yardley DA, Burris HA 3rd, Hainsworth JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2009 Dec;4(12):1555-60. doi: 10.1097/JTO.0b013e3181bbc540. PMID 19875975